Anzeige
Mehr »
Dienstag, 10.03.2026 - Börsentäglich über 12.000 News
Das Triple-Discovery-Setup, das der Markt noch nicht begriffen hat!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMBV | ISIN: DK0061804770 | Ticker-Symbol: LDBA
Frankfurt
10.03.26 | 10:33
5,175 Euro
+4,04 % +0,201
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
H LUNDBECK A/S B Chart 1 Jahr
5-Tage-Chart
H LUNDBECK A/S B 5-Tage-Chart
RealtimeGeldBriefZeit
5,1955,21011:58
5,1905,21011:55
PR Newswire
197 Leser
Artikel bewerten:
(1)

H. Lundbeck A/S: Lundbeck appoints Chief AI Officer

VALBY, Denmark, March 10, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will join the Executive Leadership Team and report to President and CEO, Charl van Zyl.

The appointment marks an important step in Lundbeck's ambition to become a bionic company. As a key pillar of Lundbeck's Focused Innovator strategy, AI plays a critical role in transforming how the company operates, innovates, and scales its impact for patients.

"As we advance our Focused Innovator strategy, becoming a bionic company is one of our key strategic focus areas," said Charl van Zyl, President and CEO of Lundbeck. "AI is not only about technology implementation. It is about transforming how we think, decide, and execute across our entire value chain. Markus brings the enterprise mindset and proven track record needed to embed AI into our business in a responsible and value-creating way."

In recent years, Lundbeck has established several strategic AI partnerships, including collaborations with OpenAI, Iambic Therapeutics and Danish Centre for AI Innovation. Together, these efforts advance research and early discovery of new drug candidates, while also accelerating commercial execution through data-driven decision-making, enhanced customer engagement and strengthened patient support. Across the enterprise, AI is strengthening operational efficiency and enabling new, scalable ways of working.

In his role as Chief AI Officer, Markus Kede will lead the continued evolution and execution of Lundbeck's global AI strategy. He will establish strong governance and responsible AI practices, build focused AI capabilities, and drive scalable deployment across functions. His mandate is to ensure clear prioritization and measurable value creation, strengthening Lundbeck's long-term competitiveness.

Markus Kede brings more than 15 years of international leadership experience across global and commercial roles in highly regulated environments. He currently serves as Senior Vice President, Finance & Business Planning for Lundbeck US, where he leads strategic and financial performance for the US organization and chairs the US Digital & AI Strategy Committee. In this capacity, he has been instrumental in defining and advancing AI initiatives and accelerating enterprise adoption of AI and automation. He will transition from his current US-based role over the coming months and is expected to assume his new role and join the Executive Leadership Team by 1 July.

Contacts

Anders Crillesen
Senior Director, Corp. Communication
AECE@lundbeck.com
+45 27 79 12 86

Jens Høyer
Vice President, Head of Investor Relations
JSHR@lundbeck.com
+45 30 83 45 01

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-appoints-chief-ai-officer,c4318694

The following files are available for download:

https://mb.cision.com/Main/18215/4318694/3973286.pdf

Press Release - Chief AI Officer - Final

https://news.cision.com/h--lundbeck-a-s/i/kede-kede-markus-003,c3517851

KEDE Kede Markus 003

Cision View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-appoints-chief-ai-officer-302709214.html

© 2026 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.